Norketotifen
Long COVID and Influenza-like Illnesses
Not Disclosed (Likely Pre-clinical/Early Clinical)Active
Key Facts
Indication
Long COVID and Influenza-like Illnesses
Phase
Not Disclosed (Likely Pre-clinical/Early Clinical)
Status
Active
Company
About Emergo Therapeutics
Emergo Therapeutics is a private, pre-revenue biotech developing immune-modulating small molecules for conditions characterized by hyperactive cytokine release, such as cytokine storms. The company's core technology focuses on curtailing cytokine release from mast cells, with its lead asset, Norketotifen, in development for long COVID and influenza-like illnesses—two areas with significant unmet need. Founded in 2016, Emergo is positioned in the large and growing market for immunology and respiratory therapeutics, though it faces risks common to early-stage drug development, including clinical trial execution and competition.
View full company profile